Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
15 June 2017
Answer given by Mr Andriukaitis on behalf of the Commission

According to Article 168 of the Treaty on the Functioning of the European Union(1), the definition of the health policy and the organisation and delivery of health service and medical care are the responsibility of the Member States, including pricing and reimbursement decisions. However, the Commission recognises the importance of timely access to innovative medicines for patients and facilitates EU cooperation in different areas concerning access to medicines.

One of the initiatives is Health Technology Assessment (HTA), which assesses the added value of given health technology over and above existing ones, helping Member States to allocate national resources to effective health interventions. The Commission launched an initiative on strengthening EU cooperation on HTA which aims at reducing discrepancies of procedures and duplication of efforts for HTA bodies and industry, discrepancies in HTA methodologies, and ensuring uptake of work jointly produced into national HTA activities.

The Commission supports the Greek authorities, in the context of the dialogue within the memorandum of understanding to cooperate and exchange information, experience and best practices with other Member States that carry out these assessments in order to increase the cost-effectiveness of public expenditure for healthcare.

Increased cooperation will help Greek authorities in making decisions for their health system that are evidence based and contribute to the development of an effective, efficient, resilient and sustainable health sector.


Last updated: 21 June 2017Legal notice